AstraZeneca names new EVP of BioPharma R&D

28 July 2023
astrazeneca_scientist_large

UK pharma major AstraZeneca (LSE: AZN) today announced that Sharon Barr has been appointed executive vice president, BioPharmaceuticals R&D.

Ms Barr will succeed Sir Mene Pangalos, who is retiring and will step down from his role early next year, after almost 14 yars with the company and an illustrious 35-year career.

Ms Barr will be responsible for discovery through to late-stage development across cardiovascular, renal and metabolism and respiratory and immunology. She will report to chief executive Sir Pascal Soriot and become a member of AstraZeneca’s senior executive team (SET) as of August 1.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical